Noor Ul Ain Rehman
Sat, May 23, 2026 astatine 7:16 AM CDT 2 min read
The standing update came aft Biodesix, Inc. (NASDAQ:BDSX) reported concern and fiscal results for fiscal Q1 2026 connected May 4, reporting that Diagnostic Testing gross reached $22.3 cardinal successful the quarter, representing 37% year-over-year growth. This was attributed to a 29% summation successful trial volumes to 17,800 and a higher mean gross per test, portion the betterment successful mean gross per trial was chiefly driven by expanded payer sum and enhancements to gross rhythm management.
Biodesix, Inc. (NASDAQ:BDSX) further reported that full gross for fiscal Q1 2026 was $25.6 million, up 42% implicit the respective prior-year comparable period, with an 84% gross margin.
Biodesix, Inc. (NASDAQ:BDSX) is simply a supplier of blood-based diagnostics services for patients with lung disease. The steadfast offers GeneStrat and VeriStrat, on with six different diagnostic tests, including: Nodify XL2, Nodify CDT, GeneStrat, VeriStrat, Bio-Rad SARS-CoV-2 ddPCR test, and the Platelia SARS-CoV-2 test.
While we admit the imaginable of BDSX arsenic an investment, we judge definite AI stocks connection greater upside imaginable and transportation little downside risk. If you're looking for an highly undervalued AI banal that besides stands to payment importantly from Trump-era tariffs and the onshoring trend, spot our escaped study connected the best short-term AI stock.
READ NEXT: 15 Stocks That Will Make You Rich successful 10 Years AND 12 Best Stocks That Will Always Grow.
Disclosure: None. Follow Insider Monkey connected Google News.

1 hour ago
1





English (CA) ·
English (US) ·
Spanish (MX) ·